Free Trial
OTCMKTS:BMXMF

bioMérieux (BMXMF) Stock Price, News & Analysis

bioMérieux logo
$116.86 +0.37 (+0.31%)
As of 01:47 PM Eastern

About bioMérieux Stock (OTCMKTS:BMXMF)

Key Stats

Today's Range
$116.86
$116.86
50-Day Range
$100.50
$116.49
52-Week Range
$93.50
$122.52
Volume
5 shs
Average Volume
1,734 shs
Market Capitalization
$13.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Receive BMXMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter.

BMXMF Stock News Headlines

Mode Mobile is poised for massive growth and looking to disrupt the $1T+ smartphone industry - Invest Today
While other cell phone carriers are always looking for ways to squeeze every last penny out of their customers, my company pays users for the 40 hours a week they are using smartphone apps, listening to music, and watching videos online with their phones. And you can join us for just $0.26 per share. Plus, when you invest now, you can get up to 100% bonus shares!
bioMérieux S.A. (BMXMF)
Berenberg Bank Keeps Their Buy Rating on bioMerieux (0RUG)
Kepler Capital Reaffirms Their Buy Rating on bioMerieux (0RUG)
bioMerieux (0RUG) Gets a Buy from Kepler Capital
See More Headlines

BMXMF Stock Analysis - Frequently Asked Questions

bioMérieux's stock was trading at $106.19 at the start of the year. Since then, BMXMF stock has increased by 10.0% and is now trading at $116.8550.
View the best growth stocks for 2025 here
.

Shares of BMXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
1/21/2025
Next Earnings (Estimated)
3/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:BMXMF
CIK
N/A
Employees
14,600
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.98 billion
Cash Flow
$5.28 per share
Book Value
$34.31 per share

Miscellaneous

Free Float
N/A
Market Cap
$13.83 billion
Optionable
Not Optionable
Beta
0.78

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:BMXMF) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners